Analytical Data
-
Gene name
FGFR2
- Application
-
Alternative Names
CD332; BEK; BFR1; CEK3; CFD1; ECT1; JWS; K-SAM; KGFR; TK14; Bacteria-Expressed Kinase,Keratinocyte Growth Factor Receptor; Craniofacial Dysostosis 1; Crouzon Syndrome
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
P21802
-
Expression Region
Thr157~Glu377
-
Molecular Weight
32kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Fibroblast growth factor receptor 2 (FGFR2) is a crucial member of the fibroblast growth factor receptor family, playing a significant role in various developmental processes, tissue repair, and cell proliferation. Abnormalities in FGFR2 signaling are often implicated in a range of diseases, particularly certain types of cancers and congenital disorders. Research into FGFR2 has gained momentum due to its association with various pathologies, including breast cancer, endometrial cancer, and craniosynostosis syndromes. The production of FGFR2 recombinant proteins has become a pivotal aspect of this research, as these proteins serve as valuable tools for studying the receptor's structure, function, and interactions at the molecular level. By utilizing recombinant DNA technology, researchers can generate large quantities of FGFR2 proteins, enabling detailed investigations into their biochemical properties, ligand-binding capabilities, and downstream signaling pathways. This understanding is crucial not only for elucidating the fundamental biology of FGFR2 but also for the development of targeted therapies aimed at modulating FGFR2 activity in disease contexts. Overall, the study of FGFR2 recombinant proteins is an essential avenue for advancing our knowledge of growth factor signaling and its implications in health and disease.
